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Abstract
Background: Detection of early stage non-small cell lung cancer (NSCLC) is commonly believed to be incidental.
Understanding the reasons that caused initial detection of these patients is important for early diagnosis. However, these
reasons are not well studied.
Methods: We retrospectively reviewed medical records of patients diagnosed with stage I or II NSCLC between 2000 and
2009 at UT MD Anderson Cancer Center. Information on suggestive LC-symptoms or other reasons that caused detection
were extracted from patients’ medical records. We applied univariate and multivariate analyses to evaluate the association
of suggestive LC-symptoms with tumor size and patient survival.
Results: Of the 1396 early stage LC patients, 733 (52.5%) presented with suggestive LC-symptoms as chief complaint. 347
(24.9%) and 287 (20.6%) were diagnosed because of regular check-ups and evaluations for other diseases, respectively. The
proportion of suggestive LC-symptom-caused detection had a linear relationship with the tumor size (correlation 0.96; with
p,.0001). After age, gender, race, smoking status, therapy, and stage adjustment, the symptom-caused detection showed
no significant difference in overall and LC-specific survival when compared with the other (non-symptom-caused) detection.
Conclusion: Symptoms suggestive of LC are the number one reason that led to detection in early NSCLC. They were also
associated with tumor size at diagnosis, suggesting early stage LC patients are developing symptoms. Presence of
symptoms in early stages did not compromise survival. A symptom-based alerting system or guidelines may be worth of
further study to benefit NSCLC high risk individuals.
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Introduction
In 2009 and 2010, lung cancer (LC) continued to have the
highest incidence and mortality of all cancers [1,2]. Most cases of
LC are found at an advanced stage and thus are associated with a
high mortality rate [3]. Recently, National Lung Screening Trial
(NLST) has shown that low-dose CT screening results in 20%
mortality reduction in individuals at high LC risk. This setting
overall reflects the large gap in the early detection of non-small cell
LC (NSCLC) that can be addressed.
Unlike advanced LC where detection is thought to be always
triggered by symptoms, detection of early stage NSCLC patients is
commonly believed to be incidental. This is because symptoms at
an earlier stage of LC are considered rare and not related to tumor
and are largely ignored [4,5,6]. Then it is important to understand
what makes early stage LC patients seek medical attention.
Because of uncertainty regarding the reasons that caused initial
detection, we retrospectively reviewed electronic medical records
to collect this information in patients diagnosed with early-stage
LC. We are interested in how often LC patients were diagnosed
because of symptoms at their early stage and whether these
symptoms were related to early-stage lung tumor, and whether the
presence of symptoms at early stage compromises survival.
Contrary to the accepted theory that early LC is asymptomatic,
symptoms was the number one reason that caused initial detection
in this study population. Furthermore symptoms showed an
association with tumor size at presentation but no association with
survival. Although the clinical usefulness of this information is not
determined and the results need to be verified by other
independent preferably prospective studies, our data indicate that
the general belief on asymptomatic early stage LC may have to be
reconsidered.
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Patients
We retrospectively reviewed the electronic medical records of
1396 patients with stage I or II, out of 4502 all stage NSCLC
patients identified through the institutional databases (Tumor
Registry and Patients’ Hidstory database) who presented between
2000 and 2009 at The University of Texas MD Anderson Cancer
Center (Houston, Texas). This study was approved by the M. D.
Anderson Cancer Center’s Office of Human Research Protections
(OHRP) with institutional review board IRB00005015 and a
waiver of informed consent because the data are analyzed
anonymously. There were no age, gender, or race restrictions.
We extracted the following types of data: age, sex, race, smoking
status, tumor stage, cell type, and follow-up therapies. The staging
was done according to the American Joint Committee on Cancer
Staging System. Information on the main reason that made
patients seek medical attention and finally led to diagnosis was
extracted from the ‘‘History of present illness’’ as recorded by a
physician during initial evaluation. Records of tumor size were
verified by surgical reports of 961 patients. For our analysis, we
used the maximum tumor size dimension.
We collected vital status (dead or alive) by the National Death
Index search. The cutoff date for all living patients was July 15,
2010. The survival time was calculated from the date of the LC
diagnosis.
Mode of Detection
We divided the reasons that made patients seek medical
attention into two main categories: suggestive LC-symptom-
caused (Briefly described as symptom-caused in this article) and
not symptom-caused (including regular check-ups, evaluation of
other diseases and unknown reasons).(Figure 1) Suggestive LC-
symptoms are considered characteristic of LC in literature [7].
Here is an example of how the doctor recorded the information at
patient’s initial evaluation.
N The patient, in December, began to have difficulty with breathing, coughing
up blood for 4 to 5 weeks, 2 times a week. He was given nebulizers with
albuterol which did not resolve. He was then seen by Dr. (omitted), a
pulmonologist, who did a chest x-ray which proved to be abnormal. He
then underwent a CT scan of the chest on 01/12/05. This revealed a
mass in the right upper lobe but no mediastinal adenopathy.
This IB stage LC patient was assigned to symptom-caused
detection group because of the obvious new symptoms which
prompted medical attention and led to diagnosis of LC. Reasons
other than symptoms are also listed in Figure 1.
We were dealing with ‘‘evaluation of other diseases’’ group (287
patients) as follows. Patients diagnosed with LC while undergoing
a preoperative evaluation (for an unrelated condition; n=50) or an
evaluation for a trauma (n=30) were attributed to the non-
symptom-caused detection group. 111 patients in ‘‘other disease’’
group were all clearly described by a doctor as being evaluated for
disease other than LC. 60 of the remaining 95 patients presented
with symptoms that are not typical for LC (e.g. gastrointestinal).
Finally, 35 patients with transient suggestive LC symptoms
thought to be unrelated to LC (e.g. those occurring on the
opposite side from detected LC), were also classified as having
incidentally detected cancer [8]. 29 (2%) patients were not aware
of any diseases or symptoms and were seen by a doctor because
they: (i) didn’t have a check-up for years; (ii) a friend or a family
member was diagnosed with cancer; or because (iii) they just
wanted a check-up without any obvious reason). 39 patients
reported suggestive LC symptoms when they were diagnosed, but
these symptoms were not the reason they sought medical care.
These patients were also classified into the non-symptom-caused
category. We performed sensitivity analyses excluding these
patients (about 6%) to reduce the effect of arbitrary grouping.
Patients in symptom-caused detection group had at least one of
the suggestive symptoms of LC that are considered characteristic
of LC. We subdivided the individual symptoms into two
subcategories. The thoracic and throat symptoms category
included cough, dyspnea, shoulder, scapula and chest pain,
wheezing, dysphagia, sore throat, and voice hoarseness. The
general symptoms category included fatigue, night sweat, weight
loss, fever, dizziness, vomiting, and edema.
Statistical Analysis
Prevalence of Symptoms. The proportion of symptom-
caused detection was evaluated overall and by age group, sex, race
and smoking status. We also looked into these groups stratified by
stage to find out the relationship between the demographic factors
and proportion of symptom-caused detection.
The Relationship of Tumor Size and Prevalence of
Symptoms. To evaluate the relation between the tumor size
and symptoms, we grouped the patients into 10 categories by using
deciles of the tumor size distribution, to obtain equal size groups
(each group contained about one hundred patients). In each
group, the mean tumor size and the proportion of symptom-
caused detection were calculated. In stage IA LC specifically, we
grouped the patients into 5 categories according to quintiles of the
tumor size distribution to illuminate the relationship between
symptom-caused detection and tumor size at that stage.
The Student’s t test, Kruskal-Wallis test, and one-way ANOVA
were used to evaluate the associations between tumor size and
symptoms. The level of significance was set at P,.05. We applied
Bonferroni correction when multiple testing was performed.
Because of deviation of the tumor size distribution from normality,
logarithmic transformation was used to calculate P values for
surgical maximum size. Univariate analyses using Kaplan-Meier
and Cox Regression were performed to determine the effect of
age, gender, ethnicity, smoking status, stage status, and the
therapy. Multivariate Cox regression was performed to determine
the effect of presence of symptoms on overall and LC-specific
survival. The multivariate Cox regression model was used to adjust
for gender, age, ethnicity, smoking status, stage, and the therapy.
All analyses were performed using SPSS software, version 16.0, for
Windows.
Results
Proportion of Symptom-Caused Detection
In this case series, the most common reason (52.5%) for patients
with early-stage NSCLC to seek medical attention and treatment
was presence of symptom, followed by regular check-ups (24.9%)
and evaluation for other diseases (20.6%). The demographic
characteristics of symptom and non-symptom groups are shown in
Table 1. In particular, for the stage IA patients, 43.1% went to
doctors because of symptoms. The most common complaints were
cough (with or without blood), dyspnea (shortness of breath), pain
(scapula and chest), fever, sore throat, weight loss, fatigue,
wheezing, voice hoarseness, dysphagia, dizziness, edema, vomit-
ing, and night sweats. The thoracic and throat symptoms were
most common as chief complaints (91%), followed by general
symptoms (fever, fatigue, or weight loss) (24.4%). Individually,
cough, dyspnea, and pain (scapula and chest) were the top three
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28.1%).
No difference in the proportion of symptom-caused detection
was observed by sex and ethnicity. Younger patients (age #68,
median) were diagnosed because of symptoms more often
compared to older patients (age .68, P,.001). Recent quitters
and current smokers presented more symptom-caused detection
than never and former smokers (P=.006). Squamous cell
carcinoma caused more symptoms than adenocarcinoma
(P,.001). Symptomatic patients were less likely to be stage IA
and had more combined therapies compared to patients with non-
symptom caused detection (P,.001). After stratification by stage,
there still was no gender or ethnicity related difference in
prevalence of symptom-caused detection (Table S1). The differ-
ence by age group was observed in stage IA (borderline significant
P=.049) and IB (P=.009). The difference by smoking status and
by cell type only existed in stage IA (P=.012, and P=.016,
respectively). The proportion of symptom-caused detection
increased along with the stage. We also observed that cough,
dyspnea, and pain were the top three reported complaints in all
stages.
Symptoms and Tumor Size
Figure 2A shows that the proportion of symptom-caused
detection had a linear relationship with the tumor size (correlation
0.96; with p,.001). Figure 2B shows the subgroups of symptom
clusters. The proportion of thoracic and throat symptoms and
general symptoms both showed a linear relationship with the
tumor size. Fever, fatigue, and weight loss were significantly more
common in patients with larger tumor size (Figure S1).
The symptom-caused detection group always had significantly
larger tumors compared with those of the no symptom-caused
detection group (Table S2). However, in stage IA patients the
difference of tumor size between symptom-caused detection group
and no symptom-caused detection group became insignificant.
This is likely due to low variation in the tumor size in stage IA
patients (by definition of stage IA). The only exception was cough
(without blood) – patients affected by it had significantly larger
tumors (P=.018) compared with the no symptom-caused
detection group in stage IA. The significance of results did not
change after sensitivity analysis (after excluding people who had
suggestive LC symptoms but resented to a doctor for reasons other
than these symptoms). The tumor size (mean: 3.01 cm) of 95
patients who presented with symptoms not suggestive of LC or
thought to be unrelated to LC showed no difference (p..05) from
the tumor size in regular check-ups group (mean: 2.69 cm) or from
that in the rest of the patients in the group diagnosed through
evaluation for other disease (mean: 3.03 cm).
Symptoms and Survival
The comparison of overall survival time between symptom-
caused detection (median, 4.42 years; 95% confidence interval
[CI], 3.27–5.56) and non-symptom-caused detection (median:
5.92 years; 95% CI4.44–7.39) showed no significant difference
Figure 1. The reasons causing initial medical attention.
doi:10.1371/journal.pone.0032644.g001
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survival time, the difference remained not significant (Log Rank,
P=.483). Figure S2 and Figure S3 show no significant difference
in the overall survival and LC specific survival stratified by stage,
respectively.
We also compared the survival after adjustment by age,
gender, race, smoking status, therapy, and stage, because these
factors may affect survival in patients with early-stage NSCLC
[9]. Table S3 shows the associations between the overall or LC
specific survival and these prognostic factors. All of them were
significantly associated with survival and were adjusted for in the
final model. Table 2 summarizes the results of the analyses of
symptoms as predictors of overall and LC-specific survival after
adjustment by age, gender, race, smoking status, therapy, and
stage. Only the comparison results of overall symptoms, two
subgroups of symptom clusters, and the top three reported
individual symptoms (cough, dyspnea, and pain) are shown, as
the small case number did not allow for comparisons by other
individual symptoms. Our results demonstrated that for the early
stages (I and II) of LC, the symptom-caused detection group
showed no significant difference in overall and LC-specific
survival when compared to the non-symptom-caused detection
group. We also tested the proportional hazards assumptions and
they were not violated.
Table 1. Demographic characteristics of patients diagnosed through symptoms and for other reasons.
Characteristics All (N=1396)
nSymptom-caused detection
(N=733)
Other detection
(N=663) P value**
Sex, n (%)
Male 725 (51.9) 377 (51.4) 348 (52.5) .693
Female 671 (48.1) 356 (48.6) 315 (47.5)
*Age, n (%)
#68 749 (53.7) 430 (58.7) 319 (48.1) ,.001
.68 647 (46.3) 303 (41.3) 344 (51.9)
Ethnicity, n (%)
White 1213 (86.9) 632 (86.2) 581 (87.6) .286
Black 98 (7.0) 53 (7.2) 45 (6.8)
Hispanic 58 (4.2) 29 (4.0) 29 (4.4)
Other 27 (1.9) 19 (2.6) 8 (1.2)
Stage, n (%)
IA 613 (43.9) 264 (36.0) 349 (52.6) ,.001
IB 429 (30.7) 245 (33.4) 184 (27.8)
IIA 88 (6.3) 46 (6.3) 42 (6.3)
IIB 266 (19.1) 178 (24.3) 88 (13.3)
Smoking, n (%)
Never 192 (13.8) 93 (12.7) 99 (15.0) 0.010
Former 713 (51.2) 355 (48.5) 358 (54.2)
Recent Quitter 167 (12.0) 104 (14.2) 63 (9.5)
Current 321 (23.0) 180 (24.6) 141 (21.3)
Cell type, n (%)
Adenocarcinoma 584 (41.8) 269 (36.7) 315 (47.5) ,.001
Squamous cell carcinoma 406 (29.1) 240 (32.7) 166 (25.0)
Bronchioloalveolar carcinoma 93 (6.7) 39 (5.3) 54 (8.1)
Others including mixed types 313 (22.4) 185 (25.2) 128 (19.3)
Therapy type, n (%)
No therapy 3 (0.2) 1 (0.1) 2 (0.3) ,.001
Surgery 741 (53.1) 341 (46.5) 400 (60.3)
Chemo 65 (4.7) 41 (5.6) 24 (3.6)
Radiation 284 (20.3) 151 (20.6) 133 (20.1)
Surgery & Chemo 182 (13.0) 115 (15.7) 67 (10.1)
Surgery & Radiation 25 (1.8) 19 (2.6) 6 (0.9)
Chemo & Radiation 76 (5.4) 52 (7.1) 24 (3.6)
Surgery & Chemo & Radiation 20 (1.4) 13 (1.8) 7 (1.1)
*Age 68 is the median.
**Determined by chi-square test.
nSymptoms suggestive of LC.
doi:10.1371/journal.pone.0032644.t001
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Contrary to what we expected, detection of early stage (I or II)
NSCLC seems not totally incidental. In our study population,
52.5% patients were detected because of symptoms suggestive of a
lung tumor. Because of the retrospective design, information on
symptoms was extracted from medical records but not directly
from interviews or surveys. Thus there might be inaccuracies in
the grouping patients into symptom-caused and non-symptom-
caused detection, due to different understanding of early LC
symptoms. To avoid an arbitrary result, we performed a sensitivity
analysis, only including individual most common symptoms:
cough, dyspnea and pain, which are accepted LC symptoms.
The total number of patients having at least one of these symptoms
is 661, still 47.3% of all early stage LC patients.
Our study challenges the general belief that LC is asymptomatic
until it reaches an advanced stage. Most suggestive LC symptoms
that prompted individuals to seek medical care showed clear
association with tumor size at diagnosis, while the non-suggestive
LC symptoms or unrelated symptoms didn’t. The proportion of
symptoms in early stage LC patients is high enough to draw
medical attention. Even in stage IA, the earliest stage that is
believed to be totally asymptomatic, the proportion of symptoms is
still remarkable and the association with tumor size is also
observable. Koyi et al. [10] reported that only 7.0% of 364
patients with LC were asymptomatic in their study. Of the 67
(18.4%) patients with stage I or stage II LC in their study, the
proportion of symptomatic patients in stage I or stage II was not
less than 62.0%, which is even higher than that in our study.
Another study by Smith et al. [11] also indicated that LC
Figure 2. The proportion of symptom-caused detection in each tumor size category: (A) overall symptom, (B) two subgroups of
symptoms.
doi:10.1371/journal.pone.0032644.g002
Initial Medical Attention on Early NSCLC Patients
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e32644(including stages III and IV) is almost always symptomatic, usually
for several months before consultation.
Although the symptom-caused detection is common in early
stage LC patients, these symptoms are usually believed not to be
related to LC and largely ignored because they are considered
non-specific [4,12,13]. However, we observed that the larger
tumor size was associated with higher prevalence of symptoms in a
close to linear way (Figure 2; P,0.0001, Symptoms that are not
suggestive of LC or unrelated to LC did not show such an
association), which implies that these symptoms might be
indicators of the early stage LC. Squamous cell lung carcinoma
usually starts near a central bronchus [14], which is likely to cause
more symptoms than peripheral LC (such as adenocarcinoma).
This is what was observed in our study: SqCC caused more
symptoms than. We also found the highest proportion of
symptom-caused detection among recent quitters, consistent with
the previous observation that ex-smokers within one year of
cessation have high standardized lung cancer mortality ratios. This
phenomenon may be explained by the so-called reverse causality
bias – symptoms compel smokers to quit, although smokers
attribute these symptoms to smoking rather than developing lung
cancer [15,16] Recent quitters and current smokers have a higher
proportion of symptom-caused detection than never and former
smokers. This implies that long standing, habitual smoking-related
symptoms do not prevent smoking patients from noticing new
symptoms, indicating existence of specific early changes in their
typical symptoms.
Symptom and non-symptom diagnosed patients showed similar
survival even if stratified by stage. One can suggest that there is a
time point when LC from curable becomes incurable, and also a
time point of symptom development. If the turning point of
curable to incurable LC occurs after symptom development, there
exists an opportunity time window, during which an appropriate
intervention can result in a cure. (Figure 3) This is consistent with
both the observation of larger tumor sizes at diagnosis and worse
stage distribution in symptom-caused versus non-symptom-caused
detected patients, and with the fact that survival does not show
much difference between these two groups.
A study by Corner et al. [5] indicated that people would not pay
attention to symptoms until the problem was so severe that it could
no longer be tolerated. In another study, Smith et al. performed a
cross-sectional quantitative interview survey of 360 patients with
newly diagnosed primary LC in three Scottish hospitals [11], and
concluded that the time between symptom onset and consultation
was long enough to plausibly affect prognosis [11]. In our study
the average time is about 2 months, which may partially explain
the larger tumor size in the symptom-caused detection group.
Smith et al. also found that hemoptysis, new onset of shortness of
breath, cough, and loss of appetite were significantly associated
with earlier consulting. Those findings are also consistent with our
findings that the main symptoms in early stage NSCLC were
cough and dyspnea.
Naruke et al [17] compared the survival of screen-detected
versus symptom-detected LC patients for all stages (I–IV) in Japan.
The symptom-detected group had significantly lower survival than
did the screen-detected group [17]. Because advanced patients
naturally have more symptoms, the results on survival were
confounded by stage and do not explain the situation of the LC at
a curable stage (stage I & II). A different study from Japan by
Sobue et al. [18] focused on stage I LC patients without surgical
treatment and also observed a poorer survival in symptomatic
versus asymptomatic patients. However, without the surgical
treatment, which is the most efficient treatment for early-stage
NSCLC, survival will depend on the extent of tumor progression.
Table 2. Analysis of symptoms as a predictor of overall and LC specific survival for stage I & II and stage IA only LC after
adjustment for age, sex, race, smoking status, stage status, and therapy.
Variable Overall survival Lung cancer specific survival
HR 95.0% CI P Value HR 95.0% CI P Value
Overall No Symptoms (I & II) 1.000 - - 1.000 - -
Overall Symptoms 1.115 0.913–1.361 .284 0.994 0.680–1.454 .977
Thoracic & throat* 1.115 0.910–1.367 .293 1.026 0.698–1.508 .895
Cough(without blood) 1.043 0.919–1.183 .518 1.124 0.898–1.408 .307
Hemoptysis 1.037 0.925–1.162 .534 0.979 0.791–1.212 .846
Dyspnea 1.099 0.958–1.261 .180 1.041 0.809–1.341 .753
Pain 1.162 0.872–1.549 .307 0.915 0.514–1.628 .762
General** 1.251 0.942–1.663 .122 1.180 0.689–2.021 .546
Overall No Symptoms (IA only) 1.000 - - 1.000 - -
Overall Symptoms 1.144 0.818–1.600 .443 0.901 0.423–1.920 .788
Thoracic & throat* 1.169 0.829–1.648 .374 1.024 0.477–2.199 .952
Cough(without blood) 1.014 0.806–1.276 .906 1.015 0.626–1.646 .952
Hemoptysis 1.228 0.976–1.546 .080 1.245 0.747–2.076 .401
Dyspnea 1.143 0.908–1.439 .256 1.114 0.720–1.725 .627
Pain 1.173 0.677–2.033 .569 1.198 0.337–4.261 .780
General** 0.995 0.571–1.734 .986 0.368 0.048–2.821 .336
*The thoracic and throat symptoms category included cough, dyspnea, shoulder, scapula and chest pain, wheezing, dysphagia, sore throat, and voice hoarseness.
**The general symptoms category included fatigue, night sweat, weight loss, fever, dizziness, vomiting, and edema.
Variables were coded as 0 for no symptom, 1 for symptom; Age, sex, race, smoking status, stage status, and therapy were adjusted for all stage I & II. Age, sex, race,
smoking status, and therapy were adjusted for stage IA by using multivariate Cox Regression.
doi:10.1371/journal.pone.0032644.t002
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of symptoms is related to a larger, likely more progressed tumor at
the time of diagnosis. (Figure 3) Another study by Raz et al. [8]
found no overall difference in stage-adjusted survival between
symptomatic LC and incidental detection, although they might
not have had statistical power to detect the difference due to the
limited sample size with 100 incidentally detected and 174
symptom detected patients.
Our study might be the largest retrospective study on symptoms
in early stage LC. The major implication is that symptoms may be
a potential alerting indicator for early-stage NSCLC but will not
necessarily compromise survival. A study in ovarian cancer,
previously believed to be asymptomatic, demonstrated that
symptoms can be used to diagnose ovarian cancer earlier (Goff
et al.). [19,20] Our data can thus be used in a model for prediction
of early-stage NSCLC.
Unlike Goff et al.’s study, our study was limited in that our
subjects were only LC patients, but controls (high-risk individuals
without LC) were not available. Acquiring the group of controls
should be the next step to determine whether the symptoms are
useful for screening in a population of high risk for LC (e.g. older
smokers). Another limitation of our study is that symptoms
identified retrospectively may be incomplete and arbitrary.
Although we performed data extraction carefully, we cannot rule
out the variations in documenting symptoms by different doctors
at the time of initial evaluation. Thus, an independent prospective
study is needed to verify our results.
Our findings suggest that the general belief that early LC is
asymptomatic should be rethought carefully, and guidelines for
earlier recognition of LC are well worth of further study. Due to
NLST results, there is a renewed interest in lung cancer screening
and an urgent need to identify highest risk group that should be
screened. Potentially the symptom based alert system, in
combination with known lung cancer risk factors, can help
identify such a group, which will increase the yield of cases and
improve screening efficiency.
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